 | Up a level |
Journal Article
Gaidzik, V., I, Weber, D., Paschka, P., Krieger, S., Kaumanns, A., Kroenke, J., Kapp-Schwoerer, S., Koehne, C-H, Horst, H-A, Schmidt-Wolf, I. G. H., Held, G., Kuendgen, A., Ringhoffer, M., Goetze, K., Kindler, T., Fiedler, W., Wattad, M., Corbacioglu, A., Bullinger, L., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Schlenk, R. F., Doehner, H. and Doehner, K. (2015). DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG). Oncol. Res. Treat., 38. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Schlenk, R. F., Paschka, P., Krauter, J., Luebbert, M., Brossart, P., Salih, H. R., Theobald, M., Fiedler, W., Wulf, G., Kirchner, H., Hertenstein, B., Heide, F., Westermann, J., Griesshammer, M., Wattad, M., Goetze, K., Girschikofsky, M., Kuendgen, A., Koller, E., Rudolph, C., Heuser, M., Thol, F., Goehring, G., Teleanu, V, Weber, D., Gaidzik, V., I, Doehner, K., Ganser, A. and Doehner, H. (2015). Clinical outcome in older AML patients not fit for intensive chemotherapy: Results of the population-based AMLSG-BiO (NCT01252485) registry study of the German-Austrian AML study group. Oncol. Res. Treat., 38. S. 121 - 123. BASEL: KARGER. ISSN 2296-5262
Schliemann, C., Pink, D., Floercken, A., Ahrens, M., Egerer, G., Goetze, K., Palmerini, E., Stacchiotti, S., Grignani, G., Rutkowski, P., Ullrich, R., Strapatsas, J., Hemmerle, T., Neri, D. and Kessler, T. (2021). A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma. Ann. Oncol., 32. S. S1127 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E. and Mueller-Tidow, C. (2015). DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy. Oncol. Res. Treat., 38. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262